Literature DB >> 35378295

No Association Between Nonalcoholic Fatty Liver Disease and Severe COVID-19? Something We Might Ignore.

Hui Gao1, Lei Xu2.   

Abstract

Entities:  

Year:  2022        PMID: 35378295      PMCID: PMC8975749          DOI: 10.1016/j.cgh.2022.03.037

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   13.576


× No keyword cloud information.
Dear Editor: I read with interest the article by Li et al, who performed large-scale 2-sample Mendelian randomization analyses to explore the relationship between nonalcoholic fatty liver disease (NAFLD) and severe COVID-19. They concluded that there is no evidence supporting that NAFLD is a causal risk factor for severe COVID-19. I have the following queries about their study. Supplementary Table 5 showed 4.31% of patients with NAFLD were diagnosed as severe COVID-19, higher than those diagnosed as nonsevere COVID-19 (1.45%). Besides, the authors performed univariate regression analysis to assess the impact of NAFLD on severe COVID-19 in Figure 2. The odds ratio was 3.06 (P = 1.07 × 10–6). The association was significant. After adjusting for the remaining risk factors, the odds ratio was 1.61 (P = .08). P value was close to 0.05 but not significant. Thus, the author concluded that NAFLD is not an independent risk factor for severe COVID-19. However, these results seem to suggest a link between NAFLD and COVID-19. I suggest that the author should perform multiple models to prove the robustness of this result in the multivariate regression analysis. Some of the upper 95% confidence intervals of odds ratio were wrong in Supplementary Table 9. The data lack decimal points, which may lead to misinterpretation. Please check again. To further test the hypothesis that other NAFLD-associated comorbid factors may causally confound the associations, I suggest that the authors perform multivariable Mendelian randomization instead of two-sample Mendelian randomization analyses in Figure 3. It could reduce bias as far as possible after adjusting for comorbid factors in multivariable Mendelian randomization. A lot of previous studies have shown that admission C-reactive protein is associated with disease severity in patients with COVID-19.2, 3, 4, 5 However, it seems that no association was found between C-reactive protein and severe COVID-19 in Figure 3. It would be better if the authors explain. Given the large impact of NAFLD and COVID-19 on human health, further studies are required to assess whether NAFLD is a risk factor for severe COVID-19 disease and requires active intervention.
  5 in total

1.  Predictors for Severe COVID-19 Infection.

Authors:  Ashish Bhargava; Elisa Akagi Fukushima; Miriam Levine; Wei Zhao; Farah Tanveer; Susanna M Szpunar; Louis Saravolatz
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

2.  Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019.

Authors:  Xiaomin Luo; Wei Zhou; Xiaojie Yan; Tangxi Guo; Benchao Wang; Hongxia Xia; Lu Ye; Jun Xiong; Zongping Jiang; Yu Liu; Bicheng Zhang; Weize Yang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

3.  Mendelian Randomization Analysis Reveals No Causal Relationship Between Nonalcoholic Fatty Liver Disease and Severe COVID-19.

Authors:  Jiuling Li; Aowen Tian; Haoxue Zhu; Lanlan Chen; Jianping Wen; Wanqing Liu; Peng Chen
Journal:  Clin Gastroenterol Hepatol       Date:  2022-02-03       Impact factor: 13.576

4.  Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.

Authors:  Tobias Herold; Vindi Jurinovic; Chiara Arnreich; Brian J Lipworth; Johannes C Hellmuth; Michael von Bergwelt-Baildon; Matthias Klein; Tobias Weinberger
Journal:  J Allergy Clin Immunol       Date:  2020-05-18       Impact factor: 10.793

5.  Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.

Authors:  Fang Liu; Lin Li; MengDa Xu; Juan Wu; Ding Luo; YuSi Zhu; BiXi Li; XiaoYang Song; Xiang Zhou
Journal:  J Clin Virol       Date:  2020-04-14       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.